Chembio Diagnostic Systems, Inc.
Chembio Lifted by HIV Test Sales
Chembio Diagnostics, a maker of rapid tests to detect HIV and other diseases, today reported its first profitable year since going public due to a double-digit surge in annual sales and a particula
Medical Company Chembio Reports $309,000 Profit
Chembio Diagnostics Inc., Medford
Maker of diagnostic medical tests
Year: Ended Dec. 31
Chembio Reports 2009 Results
Conference Call Scheduled for Friday, March 5, 2010, at 10:30 a.m. Eastern Time
Self-Testing Easy And Accurate
Chembio to Host Conference Call to Discuss 2009 Financial Results
Conference Call Scheduled for Friday, March 5th at 10:30 a.m. Eastern Time
Chembio Diagnostics, Inc. (OTC.BB:CEMI), which develops, manufactures, markets and licenses point of care diagnostic tests, announced today that the Company will release financial results for 2009, before the open of the market on Friday, March 5, 2010. The Company's 10-K and earnings press release will be available immediately after 9:00 a.m. on our web site.
Paradigm Shift in Hepatitis C Testing May Curb the Numbers Affected, Says Expert
The Institute of Medicine, a branch of the US National Academy of Sciences, is urging healthcare providers to take steps to battle liver-damaging hepatitis B and C, which are often overlooked viruses. Surprisingly, hepatitis B and C together infect three to five times more Americans than the AIDS virus does. In the next 10 years, these two liver-damaging infections will kill about 150,000 people in the US alone, says a new Institute of Medicine report.
Chembio Enters $900,000 Development Contract With Contractor to CDC for Point of Care Influenza Test
Chembio Diagnostics, Inc. (OTC.BB:CEMI), a NY-based company that develops, manufactures, licenses and markets proprietary rapid diagnostic tests, entered into a milestone based development agreement for up to approximately $900,000 in connection with the development and initial supply of a multiplex rapid point-of-care ("POC") influenza immunity test. The test will utilize Chembio's patented Dual Path Platform (DPP®) technology. The agreement contemplates a period of approximately nine months in which the development activity is to be completed.
Point-Of-Care Testing Becomes Crucial As STD Cases Among Younger Set Continue To Rise
Sexually spread diseases continue to rise, with reported chlamydia cases setting yet another record in 2008, officials at the Centers for Disease Control recently reported. The CDC estimates that approximately 19 million new STD infections occur each year. Approximately half of them occur in young people between 15 to 24 years of age.
Chembio CEO Featured in Newsday’s Executive Suite Column for Company’s Best Quarterly Earnings Results Despite Recession
Lawrence Siebert, Chief Executive Officer, Chembio Diagnostics, Inc. (OTCBB: CEMI), which develops, manufactures, markets and licenses point-of-care diagnostic tests, was recently featured in Newsday, a suburban Long Island, New York daily newspaper. The company’s best quarterly earnings results were touted in an article by Emi Endo in the daily American newspaper, which has the eleventh highest circulation in the United States and highest for a suburban paper.
Rapid Testing: “Quick” Way To Reduce Healthcare Costs
With one hundred days down and hundreds more to go, President Obama has yet to tackle one of his most daunting tasks: healthcare reform. Most Americans agree that the healthcare system is in critical need of improvement, but the question of how to reduce healthcare costs without compromising the quality of treatments still remains.
